T8	Exp 122 138	the tumour cells
T9	Exp 275 290	the interaction
T10	Exp 374 376	we
T11	Exp 481 486	which
T12	Exp 460 474	the mRNA level
T13	Exp 498 518	the EBV oncogenicity
T14	Exp 362 372	this study
T15	Exp 601 605	that
T16	Exp 724 746	The EBNA transcription
T17	Exp 858 866	the lack
T18	Exp 1018 1029	the tumours
T19	Exp 967 979	neither LMP1
T20	Exp 1055 1073	the BamHI-A region
T21	Exp 1077 1093	the viral genome
T22	Exp 1225 1229	them
T23	Exp 1250 1254	that
T24	Exp 1139 1150	the product
T25	Exp 1255 1271	the tumour cells
T26	Exp 1547 1548	I
T27	Exp 1350 1367	our previous data
T28	Exp 1457 1461	that
T29	Exp 1420 1437	the protein level
T30	Exp 1462 1475	the programme
T31	Exp 1504 1514	the tumour
T32	Exp 1617 1629	the majority
T33	Exp 1318 1332	These findings
R3	Coref Anaphora:T11 Antecedent:T12
R4	Coref Anaphora:T22 Antecedent:T34
T1	Protein 669 697	EBV nuclear antigen (EBNA) 1
T2	Protein 712 717	EBNA2
T3	Protein 870 875	EBNA2
T4	Protein 882 914	Latent membrane protein (LMP) 2A
T5	Protein 975 979	LMP1
T6	Protein 984 989	LMP2B
T7	Protein 1124 1129	BZLF1
T34	Exp 1038 1049	Transcripts
